requests-for-proposal

Natural Ingredients for Cerebral Circulation Improvement

Request Number REQ6363872
Due Date February 9, 2018
Request for Proposal Details
RFP Title
Natural Ingredients for Cerebral Circulation Improvement
RFP Description

NineSigma, representing a multibillion-dollar global manufacturer, seeks natural compounds, ingredients and materials that improve cerebral circulation to prevent dementia. A proposal will be welcomed as far as the material or the ingredient is effective in improving cerebral circulation, regardless of whether the active ingredient or compound has been chemically identified or not.

Background

As the human lifespan is increasing, the number of patients with dementia is also increasing worldwide. It is estimated that there will be over 100 million patients with this disease by 2050. As dementia significantly deteriorates the QOL of the patient and their family, the increasing number of patients is becoming a social concern. Nevertheless, no effective treatment or preventive measure has been established, and their development is thus a pressing matter.

 

The client has strived to develop a technology to prevent the onset of dementia by improving cerebral circulation. Improved blood circulation helps prevent buildup of waste in the brain, which can be a cause of dementia. Currently, researchers around the world have studied various compounds from the viewpoint of dementia prevention. Therefore, the client has issued this open request to accelerate its development activities to prevent dementia by identifying a promising ingredient at an early date.

 

Key Success Criteria

Requirements of the proposed technology

  • The effect of improving cerebral circulation has been demonstrated in either of the following studies:
    • In vivo assessment
    • Study in humans
  • Should be derived from natural product. The active compound need not have been chemically identified.
  • Should be safe to intake orally.

 

Possible Approaches

ANTICIPATED MECHANISMS

Anticipated mechanisms include, but are not limited to, the following:

  • Phosphodiesterase (PDE) 3 inhibition
  • Rho kinase (Rho-associated coiled-coil forming protein kinase: ROCK) inhibition
  • Nitrogen oxide production

 

ANTICIPATED PROJECT PHASES OR PROJECT PLAN

Respondents should submit proposals using the attached Response Template.

 

The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

 

Approaches not of interest

APPROACHES NOT OF INTEREST

The following ingredients and materials are not of interest:

  • Ginkgo leaf extract
  • Pine bark-derived polyphenol

 

Preferred Collaboration types
  • Joint Development
  • Contract Research
  • Technology Licensing
  • Supply Agreement
Items to be submitted

Responses will use the Proposal Template, which is available here, and include the following items:

 

  • Overview of the technology
  • Natural product used as a raw material
  • Uniqueness of the technology
  • Mechanism of improved blood circulation and experimental or logical evidence
  • Development stage
  • Data showing the effect of improving blood circulation
    • Test conditions
    • Test results
  • Information about the safety of oral intake
  • Current challenges and future development plan
  • Sample test conditions (sample amount that can be provided, cost, time period required for preparation, agreement conditions, etc.)
  • Prospect of mass production
  • Past achievements (additional information indicating R&D capabilities, such as research papers and patents)
  • Organization overview

 

Area of Interest
Request Priority
Comments